Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Period	Net Profit Margin
2018-06-30	-26562.18%
2019-06-30	157.32%
2020-06-30	N/A
2021-06-30	-166.40%
2022-06-30	N/A
2023-06-30	N/A
2024-06-30	-1269.15%
2025-06-30	-49290.48%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KZIA	$8.98	-6.65%	0.28M
3
4
5

Kazia Therapeutics Limited (KZIA) Profit Margin

Profit Margin Data

Get Kazia Therapeutics Limited Data in Excel

More KZIA Financial Data